AR035759A1 - Compuestos acilurea antagonistas de la funcion mpc-1, un procedimiento para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos - Google Patents

Compuestos acilurea antagonistas de la funcion mpc-1, un procedimiento para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos

Info

Publication number
AR035759A1
AR035759A1 ARP020100728A ARP020100728A AR035759A1 AR 035759 A1 AR035759 A1 AR 035759A1 AR P020100728 A ARP020100728 A AR P020100728A AR P020100728 A ARP020100728 A AR P020100728A AR 035759 A1 AR035759 A1 AR 035759A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
optionally substituted
aryl
cycloalkyl
heteroaryl
Prior art date
Application number
ARP020100728A
Other languages
English (en)
Original Assignee
Telik Inc
Sanwa Kaguku Kenkyusho Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telik Inc, Sanwa Kaguku Kenkyusho Co Ltd filed Critical Telik Inc
Publication of AR035759A1 publication Critical patent/AR035759A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Un compuesto acilurea de fórmula (1), (2) o (3) en la cual: n es un entero de 0 a 4 en fórmula (1), y es un entero de 0 a 2 en fórmula (2) y fórmula (3); X e Y están independientemente O, S, CH-R8, o N-R7 en fórmula (1) y Fórmula (2), y son independientemente N y C-R7 en la fórmula (3); Z es N o C-R8; con la condición de que por lo menos uno de X, Y y Z es un átomo de anillo que no es de carbono; cada R1 es independientemente, alquilo inferior opcionalmente sustituido, alquenilo, alquinilo, cicloalquilo, cicloalquil(alquilo inferior), heterocicloalquilo opcionalmente sustituido, arilo, opcionalmente sustituido, heteroarilo opcionalmente sustituido, arilo opcionalmente sustituido (alquilo inferior), halo (alquilo inferior), -CF3, halógeno, nitro, -CN, -OR9, -SR9, -NR9R10, -NR9 (carboxi(alquilo inferior)), -C(=O)R9, -C(=O)OR9, -C(=O)NR9R10, -OC(=O)R9, -SO2R9, -OSO2R9, -SO2NR9R10, -NR9SO2R10 o -NR9C(=O)R10, donde R9 y R10 son independientemente, hidrógeno, alquilo inferior opcionalmente sustituido, alquilo inferior -N(alquilo C1-2)2, alquilo inferior (heterocicloalquilo opcionalmente sustituido), alquenilo, alquinilo, cicloalquilo opcionalmente sustituido, cicloalquilo (alquilo inferior), heterocicloalquilo (alquilo inferior) opcionalmente sustituido, arilo (alquilo inferior), arilo opcionalmente sustituido, heteroarilo, heteroarilo (alquilo inferior), o R9 y R10 conjuntamente son -(CH2)4-6- opcionalmente interrumpido con uno de O, S, NH, N-(arilo), N-(aril(alquilo inferior)), -N-(CH2)1-6C(=O)OR10 o un grupo N- (alquilo C1-2 opcionalmente sustituido), o en la fórmula (1), n=2 y los dos R1' conjuntamente constituyen =O; R2, R3 y R8 son independientemente, hidrógeno, alquilo inferior opcionalmente sustituido, alquenilo, alquinilo, cicloalquilo, cicloalquil (alquilo inferior), heterocicloalquilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, aril (alquilo inferior) opcionalmente sustituido, halo (alquilo inferior), -CF3, halógeno, nitro, -CN, -OR9, -SR9, -NR9R10, -NR9(CH2)1-6C(=O)OR10, -C(=O)R9, -C(=O)OR9, -C(=O)NR9R10, -OC(=O)R9, -SO2R9, -OSO2R9, -SO2NR9R10, -NR9SO2R10 o -NR9C(=O)R10, donde R9 y R10 son independientemente, hidrógeno, alquilo inferior opcionalmente sustituido, alquilo inferior-N(alquilo C1-2)2, alquilo inferior (heterocicloalquilo opcionalmente sustituido), alquenilo, alquinilo, cicloalquilo opcionalmente sustituido, cicloalquil (alquilo inferior), heterocicloalquilo (alquilo inferior) opcionalmente sustituido, aril (alquilo inferior), arilo, opcionalmente sustituido, heteroarilo, heteroaril (alquilo inferior),o R9 y R10 conjuntamente son -(CH2)4-6- opcionalmente interrumpidos con uno de O, S, NH, N-(arilo), N-(aril (alquilo inferior)), N-(CH2)1-6C(=O)OR10 o un grupo N-(alquilo C1-2 opcionalmente sustituido); cada R7 es independientemente, hidrógeno, alquilo inferior opcionalmente sustituido, alquenilo, alquinilo, cicloalquil (alquilo inferior), arilo, arilo sustituido, aril (alquilo inferior), arilo (alquilo inferior) sustituido, halo (alquilo inferior), -C(=O)R9, -C(=O)OR9, -C(=O)NR9R10, -SO2OR9, -SO2NR9R10, donde R9 y R10 son independientemente, hidrógeno, alquilo inferior opcionalmente sustituido, alquilo inferior -N(alquilo C1-2)2, alquilo inferior (heterocicloalquilo opcionalmente sustituido), alquenilo, alquinilo, cicloalquilo opcionalmente sustituido, cicloalquilo (alquilo inferior), heterocicloalquilo (alquilo inferior) opcionalmente sustituido, aril (alquilo inferior), arilo opcionalmente sustituido, heteroarilo, heteroarilo (alquilo inferior), o R9 y R10 conjuntamente son -(CH2)4-6- opcionalmente interrumpido con uno de O, S, NH, N-(arilo), N-(aril (alquilo inferior)), N-(CH2)1-6C(=O)OR10 o un grupo N-(alquilo C1-2 opcionalmente sustituido); R4 y R5 son independientemente, hidrógeno, alquilo inferior, alquilo inferior opcionalmente sustituido, arilo opcionalmente sustituido, o aril (alquilo inferior) opcionalmente sustituido, o, conjuntamente, son -(CH2)2-4-; R6 es hidrógeno, alquilo inferior opcionalmente sustituido, alquenilo, alquinilo, cicloalquilo, cicloalquil (alquilo inferior), heterocicloalquilo opcionalmente sustituido, arilo opcionalmente sustituido, aril (alquilo inferior) opcionalmente sustituido, heteroarilo opcionalmente sustituido, heteroaril (alquilo inferior) opcionalmente sustituido, -C(=O)R11, -C(=O)OR11, -C(O)NR11R12, -SO2R11 o -SO2NR11R12, donde R11 y R12 son independientemente, hidrógeno, alquilo inferior opcionalmente sustituido, alquenilo, alquinilo, cicloalquilo, cicloalquilo (alquilo inferior), arilo, ariloxi opcionalmente sustituido, heteroarilo, heteroaril (alquilo inferior), o R11 y R12 conjuntamente son -(CH2)4-6; o una sal farmacéuticamente aceptable del mismos opcionalmente en forma de un estereoisómero único o una mezcla de estereoisómeros del mismo; un procedimiento para su preparación, composición farmacéutica y el uso de dichos compuestos para la preparación de medicamentos, en el cual el desorden o enfermedad alérgico, inflamatorio, o autoinmune está seleccionado del grupo que consiste en asma, arteriosclerosis, glomerulonefritis, pancreatitis, restenosis, artritis reumatoide, nefropatía diabética, fibrosis pulmonar, enfermedad inflamatoria del intestino, enfermedad de Crohn y rechazo a los trasplantes.
ARP020100728A 2001-03-01 2002-02-28 Compuestos acilurea antagonistas de la funcion mpc-1, un procedimiento para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos AR035759A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27279201P 2001-03-01 2001-03-01

Publications (1)

Publication Number Publication Date
AR035759A1 true AR035759A1 (es) 2004-07-07

Family

ID=23041292

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020100728A AR035759A1 (es) 2001-03-01 2002-02-28 Compuestos acilurea antagonistas de la funcion mpc-1, un procedimiento para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos

Country Status (15)

Country Link
US (2) US6809113B2 (es)
EP (1) EP1363897B1 (es)
JP (1) JP4291576B2 (es)
KR (1) KR20040018336A (es)
CN (1) CN1259315C (es)
AR (1) AR035759A1 (es)
AT (1) ATE313537T1 (es)
BR (1) BR0207750A (es)
CA (1) CA2439849A1 (es)
DE (1) DE60208159T2 (es)
ES (1) ES2254653T3 (es)
HK (1) HK1060728A1 (es)
MX (1) MXPA03007861A (es)
TW (1) TWI245761B (es)
WO (1) WO2002070509A2 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60144284D1 (de) 2000-11-01 2011-05-05 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
WO2006029173A2 (en) * 2004-09-08 2006-03-16 Boys Town National Research Hospital Treatment of glomerular basement membrane disease involving matrix metalloproteinase-12
MX2007012082A (es) 2005-03-31 2007-11-20 Pfizer Prod Inc Derivados de ciclopentapiridina y tetrahidroquinolina.
WO2007066496A1 (en) * 2005-12-07 2007-06-14 Sumitomo Chemical Company, Limited Benzoylurea compound and use thereof
US7601716B2 (en) * 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
CA2658719A1 (en) * 2006-07-24 2008-01-31 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
US20080076120A1 (en) * 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
DK2091948T3 (da) 2006-11-30 2012-07-23 Probiodrug Ag Nye inhibitorer af glutaminylcyclase
CA2672229A1 (en) * 2006-12-14 2008-06-19 Actogenix N.V. Delivery of binding molecules to induce immunomodulation
CA2679446C (en) 2007-03-01 2016-05-17 Probiodrug Ag New use of glutaminyl cyclase inhibitors
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8356920B2 (en) * 2007-12-12 2013-01-22 Levine Jonathan E Lighting device
WO2010068881A1 (en) * 2008-12-12 2010-06-17 Forest Laboratories Holdings Limited Novel benzodioxane and benzoxazine derivatives useful as cc chemokine receptor ligands
MX2012002993A (es) 2009-09-11 2012-04-19 Probiodrug Ag Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
EP2522341A1 (en) * 2011-05-13 2012-11-14 Tragex Pharma Pharmaceutical compositions comprising Neuropilin inhibitors, and their use for the prevention and/or treatment of angiogenic disorders and cancers
RU2720237C2 (ru) 2013-11-18 2020-04-28 Форма Терапеутикс, Инк. Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
ES2860695T3 (es) 2013-11-18 2021-10-05 Forma Therapeutics Inc Composiciones de tetrahidroquinolina como inhibidores de bromodominio BET
EP4252629A3 (en) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
EP3554541B1 (en) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
US11351227B2 (en) * 2017-04-27 2022-06-07 Washington University Chemokine decoy receptors of rodent gammaherpesviruses and uses thereof
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
EP3643711A1 (en) 2018-10-24 2020-04-29 Bayer Animal Health GmbH New anthelmintic compounds
EP3883634A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
EP4309722A2 (en) 2019-12-13 2024-01-24 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE32700B1 (en) 1968-02-03 1973-10-31 Beecham Group Ltd Penicillins
GB1250611A (es) 1968-02-03 1971-10-20
DE2131034A1 (de) 1971-06-23 1973-01-11 Hoechst Ag Acylharnstoffe und verfahren zu ihrer herstellung
DE2652004C3 (de) 1976-11-15 1979-09-13 Basf Ag, 6700 Ludwigshafen l-Acyl-2-arylamino-2-imidazoline, Verfahren zu ihrer Herstellung und ihre Verwendung
US4163784A (en) 1978-03-09 1979-08-07 Pfizer Inc. Heterocyclylcarbonyl derivatives of urea, agents for dissolution of gallstones
GB8528234D0 (en) 1985-11-15 1985-12-18 Wyeth John & Brother Ltd Heterocyclic compounds
JP2650055B2 (ja) 1988-11-28 1997-09-03 キヤノン株式会社 電子写真感光体
FR2672888B1 (fr) 1991-02-14 1994-02-04 Fabre Medicament Pierre Nouvelles urees et thiourees, leur preparation et leur application en therapeutique.
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
WO1997024325A1 (en) 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS
JPH09255572A (ja) 1996-03-26 1997-09-30 Takeda Chem Ind Ltd ケモカイン受容体拮抗剤
US6686353B1 (en) 1996-05-20 2004-02-03 Teijin Intellectual Property Center Limited Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists
CA2259927A1 (en) 1996-07-12 1998-01-22 Leukosite, Inc. Chemokine receptor antagonists and methods of use therefor
EP0916668A4 (en) 1996-07-29 2000-08-16 Banyu Pharma Co Ltd CHEMOKINE RECEPTOR ANTAGONISTS
US6184235B1 (en) 1996-08-14 2001-02-06 Warner-Lambert Company 2-phenyl benzimidazole derivatives as MCP-1 antagonists
WO1998027815A1 (en) 1996-12-20 1998-07-02 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
GB9716656D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
JP2002502844A (ja) 1998-02-03 2002-01-29 ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト ５員複素環縮合ベンゾ誘導体、その調製及び医薬品としてのそれらの使用
KR20010072080A (ko) 1998-07-31 2001-07-31 쓰끼하시 다미까따 페닐아졸 화합물, 그의 제조 방법 및 고지혈증용 약제
US6316449B1 (en) 1999-07-08 2001-11-13 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists
US6777413B2 (en) 2000-02-01 2004-08-17 Millennium Pharmaceuticals, Inc. 2-[1H]-quinolone and 2-[1H]-quinoxalone inhibitors of factor Xa
AU2001236606A1 (en) 2000-02-01 2001-08-14 Cor Therapeutics, Inc. 3,4-dihydro-2h-benzo(1,4)oxazine inhibitors of factor xa
AU2001230537A1 (en) 2000-02-01 2001-08-14 Daiichi Pharmaceutical Co., Ltd. Pyridoxazine derivatives

Also Published As

Publication number Publication date
DE60208159D1 (de) 2006-01-26
MXPA03007861A (es) 2004-10-15
US6809113B2 (en) 2004-10-26
WO2002070509A8 (en) 2003-11-06
US20050054668A1 (en) 2005-03-10
CN1494539A (zh) 2004-05-05
ATE313537T1 (de) 2006-01-15
US20030105085A1 (en) 2003-06-05
US7297696B2 (en) 2007-11-20
JP4291576B2 (ja) 2009-07-08
EP1363897A2 (en) 2003-11-26
CN1259315C (zh) 2006-06-14
JP2004527503A (ja) 2004-09-09
DE60208159T2 (de) 2006-08-17
WO2002070509A3 (en) 2003-05-30
ES2254653T3 (es) 2006-06-16
KR20040018336A (ko) 2004-03-03
CA2439849A1 (en) 2002-09-12
TWI245761B (en) 2005-12-21
EP1363897B1 (en) 2005-12-21
HK1060728A1 (en) 2004-08-20
BR0207750A (pt) 2004-03-23
WO2002070509A2 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
AR035759A1 (es) Compuestos acilurea antagonistas de la funcion mpc-1, un procedimiento para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
AR035743A1 (es) Compuestos de acilurea, composiciones farmaceuticas que los comprenden, uso de dichos compuestos en la preparacion de medicamentos y procesos para la preparacion de dichos compuestos.
AR035801A1 (es) Compuestos de acilurea, composiciones farmaceuticas que los comprenden, uso de dichos compuestos en la preparacion de medicamentos, y procesos para la preparacion de dichos compuestos
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
AR049398A1 (es) Derivados de sulfamato y sulfamida; una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento util para el tratamiento de la epilepsia y trastornos relacionados.
WO2003024967A3 (en) Indolizines as kinase protein inhibitors
AR054035A1 (es) Derivados benzodioxano y benzodioxolano y uso de los mismos
MX2007012936A (es) Derivados de dihidrobenzofurano y usos de los mismos.
AR049333A1 (es) Azaindoles inhibidores de proteinquinasas rock y otras proteinas quinasas. composiciones farmaceuticas.
EA200600364A1 (ru) Производные (тио)карбамоилциклогексана в качестве антагонистов d/dрецептора
RU2010116253A (ru) Производные n-гидроксилсульфонамида как новые физиологически применимые доноры нитроксила
CO5031253A1 (es) Antagonistas receptores y5 de neuropeptidos composiciones farmaceuticas que las contienen
UY25804A1 (es) Derivados de 4-aroilpiperidina que son antagonistas de los receptores ccr-3
AR061858A1 (es) Compuestos heterociclicos de fosfonatos y fosfinatos, composiciones farmaceuticas que los contienen y usos como agentes antidiabeticos.
MXPA03011638A (es) Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
AR033379A1 (es) Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
PE20061156A1 (es) Derivados de benzamida como agentes inhibidores del transportador de glicina
AR057770A1 (es) Inhibidores de la p38-map-quinasa y composicion farmaceutica
BR0215017A (pt) Lactamas como antagonistas da taquiquinina
AR048567A1 (es) Derivados de benzoxazinona, su preparacion y composiciones farmaceuticas.
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
RU2007125661A (ru) Арилоксиэтиламиновые и фенилпиперазиновые производные с сочетанием свойств неполного агонизма к рецепторам дофимина-d2 и ингибирования повторного поглощения серотонина
HUP0201356A2 (hu) Ösztrogén agonisták/antagonisták alkalmazása depresszió kezelésére vagy a kognitív funkció romlásának megelőzésére alkalmas gyógyászati készítmény előállítására
AR063374A1 (es) Derivados de benzoxazina y sus usos
AR049512A1 (es) Derivados de tetrahidrofurano tetraciclicos. composiciones farmaceuticas

Legal Events

Date Code Title Description
FB Suspension of granting procedure